HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity
eLife · 2025
DOI: 10.7554/elife.104441 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Karen Giménez-Orenga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Escuela de Doctorado, Catholic University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Endogenous Retroviruses, Fatigue Syndrome, Chronic, Fibromyalgia, Virus Activation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ME Research UK, Generalitat Valenciana.
Abstract (Originalsprache)
Research of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM), two acquired chronic illnesses affecting mainly females, has failed to ascertain their frequent co-appearance and etiology. Despite prior detection of human endogenous retrovirus (HERV) activation in these diseases, the potential biomarker value of HERV expression profiles for their diagnosis, and the relationship of HERV expression profiles with patient immune systems and symptoms had remained unexplored. By using HERV-V3 high-density microarrays (including over 350k HERV elements and more than 1500 immune-related genes) to interrogate the transcriptomes of peripheral blood mononuclear cells from female patients diagnosed with ME/CFS, FM, or both, and matched healthy controls ( n = 43), this study fills this gap of knowledge. Hierarchical clustering of HERV expression profiles strikingly allowed perfect participant assignment into four distinct groups: ME/CFS, FM, co-diagnosed, or healthy, pointing at a potent biomarker value of HERV expression profiles to differentiate between these hard-to-diagnose chronic syndromes. Differentially expressed HERV–immune–gene modules revealed unique profiles for each of the four study groups and highlighting decreased γδ T cells, and increased plasma and resting CD4 memory T cells, correlating with patient symptom severity in ME/CFS. Moreover, activation of HERV sequences coincided with enrichment of binding sequences targeted by transcription factors which recruit SETDB1 and TRIM28, two known epigenetic silencers of HERV, in ME/CFS, offering a mechanistic explanation for the findings. Unexpectedly, HERV expression profiles appeared minimally affected in co-diagnosed patients denoting a new nosological entity with low epigenetic impact, a seemingly relevant aspect for the diagnosis and treatment of this prevalent group of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Escuela de Doctorado, Catholic University of Valencia, Valencia, Spain.
- National Health Service, Manises Hospital, Valencia, Spain.
- Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, United States.
- Department of Pathology, School of Health Sciences, Catholic University of Valencia, Valencia, Spain.
ORCID-Profile: Karen Giménez-Orenga, Eva Martín-Martínez, Lubov Nathanson, Elisa Oltra
Förderung
- ME Research UK
- Generalitat Valenciana
Zitieren
APA
Giménez-Orenga, K., Martín-Martínez, E., Nathanson, L., & Oltra, E. (2025). HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity. eLife. https://doi.org/10.7554/elife.104441
Vancouver
Giménez-Orenga K, Martín-Martínez E, Nathanson L, Oltra E. HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity. eLife. 2025. doi:10.7554/elife.104441
BibTeX
@article{GimnezOrenga2025,
author = {Giménez-Orenga, Karen and Martín-Martínez, Eva and Nathanson, Lubov and Oltra, Elisa},
title = {HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.104441}
}
EUVIMED